Third Harmonic Bio Overview
Valuation check: THRD's ROE is -9.48%, below the sector sector average of 11.73%.
Get informed when a big investor buys or sells
+ Follow-9.48%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for THRD is -9.48%. That is below the sector sector average of 11.73%. Investors often review this figure alongside Third Harmonic Bio's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, THRD currently prints -9.48% for ROE, while the sector average sits near 11.73%. That is roughly 180.8% below the sector mean. Large gaps often invite a closer look at Third Harmonic Bio's growth, margins, and balance sheet.
Return on Equity shows how effectively Third Harmonic Bio converts resources into returns. At -9.48%, THRD may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting THRD's ROE (-9.48%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
